Andrew Komjathy's most recent trade in Astria Therapeutics Inc was a trade of 225,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 21, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Astria Therapeutics Inc | Andrew Komjathy | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2025 | 225,000 | 225,000 | - | - | Stock Option (Right to Buy) | |
| Astria Therapeutics Inc | Andrew Komjathy | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 175,000 | 175,000 | - | - | Stock Option (Right to Buy) | |
| Astria Therapeutics Inc | Andrew Komjathy | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2023 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Astria Therapeutics Inc | Andrew Komjathy | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 55,000 | 55,000 | - | - | Stock Option (right to buy) | |
| Astria Therapeutics Inc | Andrew Komjathy | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 6.70 per share. | 19 Nov 2021 | 100 | 100 (0%) | 0% | 6.7 | 670 | Common Stock |
| Astria Therapeutics Inc | Andrew Komjathy | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 600,000 | 600,000 | - | - | Stock Option (right to buy) |